Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$15.01 – $15.07
0% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $748.1M | $910.9M | $1.10B | $1.09B | $1.23B | $1.57B | $1.86B | $2.06B |
| Cost of revenue | $291.5M | $354.3M | $416.0M | $426.0M | $477.0M | $618.0M | $713.0M | $767.0M |
| Gross profit | $456.7M | $556.6M | $685.4M | $667.0M | $755.0M | $948.0M | $1.15B | $1.29B |
| Gross margin | 61.0% | 61.1% | 62.2% | 61.1% | 61.3% | 60.5% | 61.7% | 62.7% |
| R&D | $56.0M | $65.9M | $78.6M | $72.0M | $91.0M | $109.0M | $159.0M | $180.0M |
| Operating income | $133.6M | $172.5M | $208.1M | $206.0M | $271.0M | $327.0M | $314.0M | $383.0M |
| EBITDA | $170.5M | $217.4M | $289.2M | $300.0M | $347.0M | $454.0M | $465.0M | $530.0M |
| Net income | $138.7M | $167.6M | $186.8M | $175.0M | $205.0M | $268.0M | $246.0M | $284.0M |
| Net margin | 18.5% | 18.4% | 17.0% | 16.0% | 16.6% | 17.1% | 13.2% | 13.8% |
| EPS (diluted) | 2.14 | 2.59 | 2.87 | 2.68 | 3.13 | 4.04 | 3.33 | 3.55 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.0B | $4.06 | $3.53–$4.60 | 1 |
| 2027 | $2.2B | $4.62 | $4.01–$5.22 | 1 |
| 2028 | $3.4B | $7.16 | $6.22–$8.10 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds BITGF.
No tracked institution reports a position in BITGF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-04-28 | $1.6500 | 2025-05-02 |
| 2024-04-26 | $1.6000 | 2024-05-03 |
No one on the platform has traded BITGF yet.
| +0.00% |
| $1.6B |
| — |
| KARBFKaro Pharma AB (publ) | $5.25 | +0.00% | $1.5B | — |
| KKPCFKaken Pharmaceutical Co., Ltd. | $26.00 | +0.00% | $985M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 4.9× earnings vs its 4.5× historical median P/E.
Fair value ≈ $13.79 · price $15.01 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.